Ischemic heart disease in women and the role of hormone therapy.
The prevalence of ischemic heart disease (IHD) has been increasing among the women in developed countries. The well recognized IHD excess in men has often obscured the fact that IHD is the leading cause of death in women. Women have atypical symptoms of IHD that lead to a delay in the diagnosis and an overall poor prognosis. Women have a delay in the onset of IHD due to the beneficial effects of their sex hormones. Postmenopausal women lose this beneficial effect of estrogen and undergo significant changes in their lipid profile, arterial pressure, glucose tolerance, and vascular reactivity that increase their risk for development of IHD. Recently there has been considerable interest in the sex hormones and their role in IHD in women. The general belief that hormone replacement therapy (HRT) has an overall beneficial effect on cardiovascular disease (CVD) in women and hence decreases CVD mortality and morbidity has not been shown in the recent multicenter prospective studies. With the availability of various types of estrogen and progestins, physicians prescribing these agents should take into consideration their varying effects on the cardiovascular system. Risk factor modifications should include diet, weight loss, regular exercise, smoking cessation and adequate control of hypertension (HTN), diabetes (DM) and hyperlipidemia. In the appropriate setting, treatment with proven beneficial agents like aspirin, beta-blockers, angiotensin converting enzyme (ACE) inhibitors and statins will help decrease the burden of IHD in women.
Raza
Jaffar Ali
JA
Section of Cardiology, Department of Medicine, The Brody School of Medicine, East Carolina University, Greenville, NC 27834-4354, USA.
Reinhart
Richard A
RA
Movahed
Assad
A
D000818:Animals; D003278:Contraceptives, Oral, Hormonal / Q000494:pharmacology; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D004967:Estrogens / Q000502:physiology*; D005260:Female; D006801:Humans; D017202:Myocardial Ischemia / Q000209:etiology / Q000503:physiopathology*; D011374:Progesterone / Q000502:physiology; D012307:Risk Factors; D020845:Selective Estrogen Receptor Modulators / Q000494:pharmacology; D012737:Sex Factors
D003278:Contraceptives, Oral, Hormonal; D004967:Estrogens; D020845:Selective Estrogen Receptor Modulators; D011374:Progesterone